56 results about "Prednisonum" patented technology

The invention discloses a 3-ketosteroid-delta1-dehydrogenase mutant and application thereof in synthesis of prednisone acetate, the mutant with high catalytic activity on cortisone acetate is obtained through screening, and a methanol-water phase (Tris-HCl buffer solution) system is adopted to increase the solubility of a substrate so as to improve the biological catalytic efficiency. In a single water phase system (Tris-HCl buffer solution) without methanol, the conversion efficiency is only 64.8% for 60g / L of cortisone acetate, and under the condition that other conditions are the same, the conversion rate in the Tris-HCl buffer solution system with methanol is increased to 92.1%, and the conversion rate is increased by 1.42 times.

The invention is suitable for the technical field of biological medicine, and provides an excess drug treatment cell as well as a preparation method and application thereof. According to the invention, human umbilical cord mesenchymal stem cells (H.P.M) treated by excessive prednisone (PRED) are used as a carrier of PRED, and the excessive PRED treatment enables the human umbilical cord mesenchymal stem cells to lose proliferation ability and activity, but retains the ability of the human umbilical cord mesenchymal stem cells to target an inflammation site. The H.P.M can accurately deliver PRED to an inflammation part, so that pH-sensitive controlled release is realized, the treatment effect is improved, and the side effect of systemic application of PRED is greatly reduced. Due to the good drug loading capacity and release stability, the effectiveness and stability of drug delivery are further improved. The excess drug treatment method can be applied to other types of cells, and other drugs can be selected as the excess drug for treating the cells, so that a breakthrough is brought to treatment of gouty arthritis, and a new way is opened up for treatment of other diseases.

The invention discloses a polymer material, a drug-loaded micelle solution, a drug-loaded micelle composite hydrogel, and a preparation method and application of the drug-loaded micelle composite hydrogel. The polymer material is obtained by reacting oxidized dextran and oleylamine; wherein the oxidized dextran is obtained by oxidizing dextran with the molecular weight of 35000 to 45000; the oxidation degree of the oxidized dextran is 55-70%; the mass ratio of the oxidized dextran to the oleylamine is 1: (1.2-2.0). The polymer material provided by the invention can form a micelle as a carrier to entrap a hydrophobic drug, such as prednisolone. The drug-loaded micelle composite hydrogel provided by the invention can be used for treating inflammatory bowel disease IBD, can avoid damage of an acid environment to a greater extent, and prolongs the administration time.

The invention belongs to the technical field of medicine detection, and particularly relates to an LCMS (Liquid Chromatography Mass Spectrometry) detection method for histamine in prednisolone. Respectively injecting the reference solution, the test solution and the blank solution into an LCMS (Liquid Chromatography Mass Spectrometer), recording a spectrogram, and calculating the content of histamine in prednisolone by adopting an external standard method; wherein the detection condition of the LCMS comprises a mobile phase, and the mobile phase adopts acetonitrile as a mobile phase A and a 10mM ammonium formate aqueous solution containing 0.1 vol% of formic acid as a mobile phase B. The method is good in reproducibility and stability and high in precision.

Provided are methods and compositions, for treating prostate cancer by administering to a patient in need thereof a therapeutically effective amount of a PARP inhibitor, e.g., niraparib; a therapeutically effective amount of a CYP17 inhibitor, e.g., abiraterone acetate, and a therapeutically effective amount of a glucocorticoid, e.g., prednisone.

The present application belongs to the field of pharmaceutical preparations, and provides a composition containing prednisolone, a preparation method thereof, and an application thereof, wherein the composition containing prednisolone comprises a matrix and prednisolone dispersed in the matrix; the matrix is ​​a copolymer of citric acid and methacrylic acid; the methacrylic acid copolymer is a methacrylic acid copolymer type A and a methacrylic acid copolymer type B. The composition of the present invention can be released at a specific point in the colon, greatly improving the effect of the drug in treating lesions in the colon.

The present disclosure relates to the use of cortisol, cortisone, cortisone acetate, hydrocortisone, fludrocortisone, prednisolone, prednisone, methylprednisolone, Dehydroepiandrosterone (DHEA), dexamethasone, betamethasone, adrenocorticotropic hormone (ACTH), ganaxolone, tetracosactide or combinations thereof for preventing and / or reducing the risk of Sudden Unexpected Death in Epilepsy (SUDEP). The disclosure further provides pharmaceutical compositions and methods for preventing and / or reducing the risk of SUDEP, particularly in Dravet Syndrome patients.

The present disclosure relates to niraparib and abiraterone acetate, plus prednisone or prednisolone; for use in a method of improving the efficacy of treatment of metastatic castration-resistant prostate cancer (mCRPC) in a patient with DNA-repair anomalies, in particular for improving the median radiographic progression-free survival (rPFS).

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

The invention discloses a compound with an anti-osteoporosis effect and a preparation method of the compound with the anti-osteoporosis effect. The preparation method comprises the following steps: separating from a fermentation solution of a fungus Talaromyces pinophilus (CICC 2707), so as to obtain new compounds, i.e., acetosellin B and acetosellin C. The invention further discloses a preparation method of the compound with the anti-osteoporosis effect and a preparation method of the compound with the anti-osteoporosis effect. Experiments show that prednisolone-induced zebra fish osteoporosis models are selected to carry out experiments on the prepared compounds acetosellin B and acetosellin C, and the compounds are found to have relatively high in-vivo osteogenic activity of zebra fish and can be used for preparing medicines for preventing and treating osteoporosis.

This invention provides a strain of *Lactobacillus plantarum*, and discloses the fermentation product of *Eucommia ulmoides* leaves, *Rehmannia glutinosa*, dried ginger, and *Dendrobium officinale* obtained by fermenting these herbs, along with its preparation method and applications. This fermentation product can directionally activate the phenylpropane biosynthetic pathway, inducing the generation of characteristic small molecule metabolites of polyphenols, particularly sanguranyl sulfadiazine (SSA). Moreover, compared to the raw materials, the fermentation product contains more active small molecule metabolites. Finally, experiments on zebrafish modeled with prednisone demonstrated that the fermentation product can significantly promote bone formation. The fermentation product mainly restores the expression levels of related genes to normal zebrafish gene expression levels by regulating these genes. Therefore, the fermentation product can be used to prepare foods or medicines that improve bone health.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

The application provides a traditional Chinese medicine composition for treating chronic primary thrombocytopenia, a preparation and application thereof, and relates to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition comprises the following traditional Chinese medicine raw materials in parts by weight: 10-50 parts of Semen Euryae, 10-50 parts of Herba Epimedii, 10-50 parts of Radix Paeoniae Alba, 10-40 parts of Radix Rehmanniae, 10-40 parts of Folium Forsythiae and 3-20 parts of Cinnamomum Cassia. Pharmacological and pharmacodynamic experimental results prove that the traditional Chinese medicine composition can obviously reduce the bleeding grade of model mice, increase the platelets of model mice, has an effect equivalent to that of prednisone acetate, and is superior to that of Jinshuye mixture. The composition can effectively treat chronic primary thrombocytopenia by regulating the kidney and the spleen, and removing the root pathogenesis of deficiency of kidney yang caused by toxic evil lingering.

The invention belongs to the technical field of chemical medicines, and particularly relates to a prednisolone hemisuccinate impurity control method, which comprises the following steps: by taking prednisolone acetate as an initial raw material, condensing, reducing, hydrolyzing and refining to obtain prednisolone. The method comprises the following steps: dissolving refined prednisolone in a succinic anhydride, pyridine and ethyl acetate system, carrying out an esterification reaction to obtain a prednisolone hemisuccinate crude product, dissolving the prednisolone hemisuccinate crude product in an organic solvent, carrying out reflux decoloration, carrying out rotary evaporation to remove the organic solvent, carrying out elutriation, filtering, and drying to obtain a prednisolone hemisuccinate refined product. According to the invention, the variety and content of 11-epihydrocortisone, prednisone, hydrocortisone and other key impurities doped in prednisolone hemisuccinate can be effectively controlled, so that the content of the obtained product is greater than 99%, the weight loss on drying is less than or equal to five thousandths, the content of all impurities is controlled to be less than 2.5 thousandths, and the purity of the prednisolone hemisuccinate is greatly improved. And a powerful quality guarantee is provided for competition of the product in the international market.

The application relates to a combination therapy for prostate cancer. The present invention provides methods and compositions for treating prostate cancer by administering to a patient in need thereof: a therapeutically effective amount of a PARP inhibitor, such as niraparib; a therapeutically effective amount of a CYP17 inhibitor, such as abiraterone acetate; and a therapeutically effective amount of a glycocortin, such as prednisone.

The invention provides application of a composition in preparation of a medicine for treating chronic nephritis, and relates to the field of traditional Chinese medicine preparations. The composition is prepared from the following components in parts by weight: 1 to 4 parts of radix rehmanniae total iridoid glycoside extract, 2 to 6 parts of fructus corni total iridoid glycoside extract and 0.5 to 1.5 parts of fructus corni total triterpene acid extract. The composition shows remarkable drug effects in the aspects of improving the survival state of rats with chronic nephritis, reducing 24-hour urine protein, reducing kidney indexes, reducing hematuria, inhibiting inflammation and the like, and has excellent multiple treatment effects, particularly, the effect of the composition in a specific combination proportion range is equivalent to that of a positive control drug prednisone acetate group, and the composition has good clinical application prospects. And the performance is even better in some indexes.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

The invention provides a method for detecting the content of aflatoxin B1, B2, G1 and G2 in prednisolone through a fermentation process, which comprises the following steps: A) dissolving a sample to be detected by adopting a solvent, performing ultrasonic extraction, and filtering to obtain a liquid to be detected; b) preparing a mixed standard control solution of aflatoxin B1, B2, G1 and G2; and C) carrying out qualitative and quantitative analysis on the to-be-detected solution and the mixed standard control solution by adopting HPLC-MS / MS to obtain a detection result. According to the method disclosed by the invention, a rapid and simple pretreatment mode is combined with high performance liquid chromatography-triple quadrupole mass spectrometry, so that the aflatoxin B1, B2, G1 and G2 detection sensitivity is high, the separation degree and peak shape are good, and the detection result is reliable.

The invention relates to the technical field of biology, in particular to a dissociation agent and a kit for progesterone determination. According to the invention, the sample dissociation agent for progesterone detection is obtained through optimized screening, and the sample dissociation agent comprises hydrocortisone, prednisolone and mono (2-ethylhexyl) phthalate (MEHP); when the dissociation agent components act independently or in a combined mode, the sensitivity to sample detection is high, the detection linear range is good, the dissociation agent is well related to a comparison reagent, the dissociation effect is improved remarkably on the whole, progesterone can be better released from corticosteroid binding protein, albumin and sex hormone binding globulin, and the progesterone dissociation agent is suitable for being used for detecting progesterone. The combination of progesterone and a captured antibody is facilitated, and the sensitivity and the accuracy can be effectively improved. Moreover, the reagent can be directly added into reagent components, so that the dissociation process and the immune reaction are carried out at the same time, the immune reaction is simple and efficient, and the reaction efficiency is improved.

The present invention discloses a method for preparing prednisolone by one-step fermentation, using Nocardia simplex as the fermentation strain, and performing C 1,2 -position dehydrogenation and C 21 -position hydrolysis in one step to convert compound I into compound IV. The optimized fermentation process of the present invention has a conversion rate of 95%-98%, few by-products, a product purity greater than 99.5%, and an overall yield of more than 80%. The present invention uses a powder-liquid mixer device that integrates microcrystallization and substrate sterilization, simplifies the pretreatment process of steroid substrates, improves production efficiency, enhances the substrate sterilization effect, does not use cosolvents, and reduces costs.

To provide a liquid or semi-solid composition comprising prednisolone valerate acetate in an amount of more than 0.15 mass% based on the total mass of the composition, which suppresses crystal precipitation when stored under low-temperature conditions.SOLUTION: A liquid or semi-solid composition comprises: (A) prednisolone valerate acetate in an amount of more than 0.15 mass% based on the total mass of the composition; and (B) a panthenol.SELECTED DRAWING: None

A prednisone enteric-coated preparation and a preparation method and use thereof are provided. The prednisone enteric-coated preparation includes: 5% to 35% of an active prednisone micro-enteric-coated preparation unit, such as an enteric-coated microsphere; and an inactive pharmaceutical adjuvant. The enteric-coated microsphere has an average particle size of 100 μm to 1,000 μm, and a dissolution behavior of the enteric-coated microsphere conforms to the provisions for enteric-coated preparations. The enteric-coated microsphere characteristic not only avoids the stimulation of prednisone to a gastric mucosa, but also makes the active ingredient quickly released and absorbed in an intestinal tract to prevent the active ingredient from being destroyed by intestinal floras. The prednisone enteric-coated preparation can be any dosage form such as a suspension or a capsule suitable for patients with difficult swallowing or normal patients.

The present disclosure provides ophthalmic compositions comprising a steroid, such as prednisolone encapsulated in a liposomal carrier and methods of use thereof.

To provide a topical therapeutic agent for skin, comprising an antedrug steroidal anti-inflammatory agent, developed to ensure both effectiveness and safety, wherein the topical application agent for skin sustains a steroid effect even after termination of drug use, suppressing recurrence of dermatitis.SOLUTION: This invention demonstrates that inclusion of an antedrug steroidal anti-inflammatory agent such as prednisolone valerate acetate, and ceramides such as N-stearoyl dihydrosphingosine (and hydrogenated soybean phospholipid) makes it possible to sustain a steroid effect even after termination of drug use, suppressing recurrence of dermatitis symptoms.SELECTED DRAWING: None

The invention discloses a method for determining prednisone acetate related substances by HPLC gradient elution, the method can simultaneously determine a plurality of impurities such as cortisone acetate, cortisone, hydrocortisone and prednisone, and the method has the advantages of strong elution ability, good separation efficiency, short detection time and simple operation, can accurately reflect the impurity content, and is suitable for industrial production. The quality control of the prednisone acetate raw material medicine is facilitated.

The invention discloses a leonurine, polygonatum polysaccharide and deoxynojirimycin pharmaceutical composition and application thereof. The pharmaceutical composition can prevent and treat diabetes and osteoporosis and other bone metabolism abnormalities caused by diabetes. Pharmacodynamic experiments show that the composition can effectively reduce blood sugar and has a definite curative effect and positive significance on improvement of juvenile zebra fish osteoporosis symptoms established by prednisolone, and the prescription proportion of the composition is optimized. The pharmaceutical composition disclosed by the invention has the advantages of simple formula, high active ingredient content, safety, effectiveness and the like.

The invention relates to the field of medicaments, and provides a prednisolone-containing composition and a preparation method and application thereof, the composition comprises a matrix and prednisolone dispersed in the matrix; wherein the matrix comprises a first matrix and colloidal silicon dioxide, and the first matrix is selected from at least one of hydroxypropyl methyl acetate succinate, hydroxypropyl methylcellulose phthalate, polyacrylic resin L100-55 and polyacrylic resin L100. The composition disclosed by the invention not only can take effect quickly, but also has a better absorption effect, and the method disclosed by the invention can be used for quickly forming the microspheres, so that the preparation time of the microspheres is greatly shortened.

The invention provides an application of metformin in preparation of a medicine for preventing or treating immune checkpoint inhibitor related colitis. It is found through experiments that when the immune checkpoint inhibitor causes colitis, change of metabolic level represented by glycolysis caused by change of a PI3K / AKT / mTOR pathway in the colon is obviously accompanied, then Treg / Th17 steady state in the colon is affected, and a high inflammatory state is shown in the colon. According to the present invention, the influence on glycolysis and other metabolic pathways is achieved through the targeted interference of the metformin on the PI3K / AKT / mTOR pathway, the colitis caused by the immune checkpoint inhibitor can be significantly improved, the anti-tumor drug effect of the immune checkpoint inhibitor is not affected, and the method is generally superior to the original clinical methylprednisolone intervention scheme.

To provide a liquid or semi-solid composition containing more than 0.15 mass% of prednisolone valerate acetate relative to the total mass of the composition, which exhibits suppressed crystal precipitation when stored under low-temperature conditions.SOLUTION: A liquid or semi-solid composition contains (A) more than 0.15 mass% of prednisolone valerate acetate relative to the total mass of the composition and (B) terpenes.SELECTED DRAWING: None

Methods for treating peripheral T-cell lymphoma include administering to a subject a combination of Cyclophosphamide, Vincristine, Prednisone, and Pralatrexate, wherein the combination does not include doxorubicin. The treatment may be administered in repeated three-week cycles, optionally including a drug holiday.